๋ชฉ์ฐจ


  • ์šฐ๋ฆฌ๋‚˜๋ผ๋Š” ์ฃผ๋กœ B gibsoni
  • 2022๋…„ B. canis ์˜ ๊ตญ๋‚ด ์ตœ์ดˆ ๋ณด๊ณ ๊ฐ€ ์žˆ์—ˆ๋‹ค.

1. Etiology & Epidemiology

  • RBC์— ๊ธฐ์ƒํ•˜๋Š” ์›์ƒ๋™๋ฌผ์ด๋‹ค.
  • Anemia ๊ด€๋ จ ์ฆ์ƒ ์ผ์œผํ‚จ๋‹ค. (ํ˜ˆ์†ŒํŒ ๊ฐ์†Œ, secondary IMHA, ITP ๋“ฑ)
  • ์ „์„ธ๊ณ„์ ์œผ๋กœ ๋ถ„ํฌํ•˜๋ฉฐ(worldwide distribution), species๊ฐ€ ๋‹ค์–‘ํ•˜๋‹ค.

  • ๊ณ ์–‘์ด๋„ ๊ฑธ๋ฆฌ๊ธฐ๋Š” ํ•˜์ง€๋งŒ, ๋“œ๋ฌผ๋‹ค. (Babesiosis in cats : less common)
    • ์ง‘๋ƒฅ์ด์—์„œ๋Š” ํŠนํžˆ ๋ณผ ์ผ์ด ์ž˜ ์—†๋‹ค.
    • ์šฐ๋ฆฌ๋‚˜๋ผ ์–‘์ฃผ์—์„œ 50๋งˆ๋ฆฌ ์ •๋„์˜ ๊ธธ๋ƒฅ์ด๋ฅผ ๋Œ€์ƒ์œผ๋กœ ๊ฒ€์‚ฌํ•ด๋ณด๋‹ˆ 15% ์ •๋„ ๊ฑธ๋ฆฐ ๊ณ ์–‘์ด๊ฐ€ ์žˆ๊ธด ํ–ˆ๋‹ค..
    • ์ˆ˜ํ˜ˆ์„ ํ†ตํ•ด ์ „ํŒŒ๋  ์ˆ˜ ์žˆ์œผ๋ฏ€๋กœ, ์ˆ˜ํ˜ˆ ์‹œ donor์˜ ํ˜ˆ์•ก ๊ฒ€์‚ฌ๊ฐ€ ํ•„์š”ํ•˜๋‹ค! (screening test)

  • B. canis, B. vogeli, B. gibsoni (pathogenic strains) ์— ๊ฐ์—ผ๋œ ๊ฒฝ์šฐ,
    • ๋ฉฐ์น ~๋ช‡ ์ฃผ์˜ incubation period ์กด์žฌ
    • Degree of parasitemia(ํ˜ˆ์•ก ์† ๊ธฐ์ƒ์ถฉ์ด ์กด์žฌํ•˜๋Š” ์ •๋„)๋Š” organism์— ๋”ฐ๋ผ ๋‹ค์–‘

  • ๊ธฐ์ƒ์ถฉ์€ RBC ๋‚ด์—์„œ ๋ณต์ œ๋˜์–ด intravascular or extravascular hemolytic anemia ๋ฅผ ์œ ๋ฐœํ•œ๋‹ค. (โ‡’ IMHA์™€ ๊ฐ๋ณ„ ํ•„์š”)
    • ๊ธฐ์ƒ์ถฉ์— ๋Œ€ํ•œ ๋ฉด์—ญ ๋ฐ˜์‘(immune-mediated reactions)์ด๋‚˜, ํ•ญ์› ๋ฐ˜์‘(altered self-antigens)์ด ์šฉํ˜ˆ์„ฑ ๋นˆํ˜ˆ์„ ์•…ํ™” โ†’ Coombs test ์–‘์„ฑ์„ ์œ ๋ฐœํ•  ์ˆ˜ ์žˆ๋‹ค.
    • Macrophage๋ฅผ ์ž๊ทนํ•œ๋‹ค โ†’ fever, hepatosplenomegaly
    • ์ ํ˜ˆ๊ตฌ๋ฅผ ๋น ๋ฅด๊ฒŒ ํŒŒ๊ดด์‹œํ‚จ๋‹ค โ†’ ์‚ฐ์†Œ๋ฅผ ์ž˜ ์šด๋ฐ˜ํ•˜์ง€ ๋ชปํ•˜๋ฏ€๋กœ severe hypoxia, 2์ฐจ์  ์žฅ๊ธฐ ์†์ƒ์„ ์œ ๋ฐœํ•  ์ˆ˜ ์žˆ๋‹ค.
    • ๊ธ‰์„ฑ ๊ฐ์—ผ๋œ ์ผ๋ถ€ ๊ฐœ์—์„œ๋Š” DIC๋กœ ์ธํ•ด ํ˜ˆ์†ŒํŒ ๊ฐ์†Œ

  • ์‹ฌ๊ฐ๋„๋Š” ๋‹ค์Œ 2๊ฐ€์ง€์˜ ์˜ํ–ฅ์„ ๋ฐ›๋Š”๋‹ค: 1) Babesia ์˜ species&strain, 2) hostโ€™s immune status
    • Chronic, subclinical๋„ ํ”ํ•˜๋‹ค. (์ฆ์ƒ์ด ์—†์–ด ์ง„๋‹จ์ด ์•ˆ ๋˜๊ธฐ๋„ / ์ ๊ทน์  ์น˜๋ฃŒ ์•ˆ ํ•ด๋„ ๋จ)
    • Glucocorticoids, splenectomy ๋Š” ๋น„์žฅ ์ข…์–‘ ๋“ฑ ๋‹ค๋ฅธ ๋ฌธ์ œ๊ฐ€ ๋™๋ฐ˜๋˜์—ˆ์„ ๋•Œ ์ง€์‹œ๋œ๋‹ค. (๋‹จ์ผ ๊ฐ์—ผ ์‹œ ๊ถŒ์žฅ๋˜์ง€ ์•Š์Œ)
    • Bartonella spp. ์™€ coinfection โ†’ ๋” ์‹ฌ๊ฐ (๊ตญ๋‚ด์—๋Š” ์ž˜ ์—†์Œ)

2. Clinical Features

๋ฏธ๊ตญ์—์„œ ์ค€์ž„์ƒํ˜•(subclinical infection)์ด ํ”ํ•จ.

Clinical forms
Peracute
Acute
Anemia & fever ์„ ์œ ๋ฐœํ•œ๋‹ค.
๋นˆํ˜ˆ โ‡’ pale MMC / tachycardia, tachypnea / depression, anorexia, weakness (๋น„ํŠน์ด์ )
์šฉํ˜ˆ์„ฑ ๋นˆํ˜ˆ โ‡’ ํ™ฉ๋‹ฌ, petechiae, hepatosplenomegaly (์‹ฌํ•œ ๊ฒฝ์šฐ ์ด‰์ง„์œผ๋กœ๋„ ๋А๊ปด์งˆ ์ˆ˜ ์žˆ์Œ)
: ๊ฐ์—ผ์˜ ๋‹จ๊ณ„, DIC์˜ ๋™๋ฐ˜ ์ •๋„์— ๋”ฐ๋ผ ๋‹ค๋ฆ„
acutesevere anemia, DIC, metabolic acidosis, renal disease
South Africa์—์„œ์˜ B. rossi ๊ฐ์—ผ์ด ๊ฐ€์žฅ ์‹ฌ๊ฐํ•˜๋‹ค.
์‹ฌ๊ฐํ•œ ๊ฒฝ์šฐ tissue hypoxemia๋„ ๋‚˜ํƒ€๋‚œ๋‹ค : ์‚ฐ์†Œ ๊ณต๊ธ‰์ด ์ค‘์š”
Acute babesiosis๋Š” ๋‹ค์Œ๊ณผ ๊ฐ๋ณ„์ง„๋‹จ ํ•„์š” : Primary IMHA & Primary ITP (PCR ๊ฒ€์‚ฌ)
ChronicWeight loss, anorexia
Atypicalํ˜ˆ์•ก์—๋Š” ์—†๋Š”๋ฐ ๋ณต์ˆ˜/์‹ฌ๋‚ญ์ˆ˜์—์„œ DNA๊ฐ€ ๊ฒ€์ถœ๋˜๊ธฐ๋„ ํ•จ.
์ „ํ˜•์ ์ธ Babesiosis ์ฆ์ƒ์ด ์—†๋”๋ผ๋„ ์ฒด์•ก์—์„œ ๊ฒ€์ถœ๋˜๋Š” ๊ฒฝ์šฐ๊ฐ€ ์žˆ์Œ.

3. Diagnosis

๋นˆํ˜ˆ์ด ์žˆ๋‹ค > Blood smear > CBC์ƒ์˜ ์ด์ƒ์ด ์‹ค์ œ๋กœ ๋นˆํ˜ˆ์ธ์ง€ / ๋ด‰์ž…์ฒด๊ฐ€ ๋ฐœ๊ฒฌ๋˜๋Š”์ง€ ํ™•์ธ!

  • Spherocytic regenerative anemia, thrombocytopenia
  • (๋น„ํŠน์ด์ ) hyperbilirubinemia, bilirubinuria, hemoglobinuria, metabolic acidosis, azotemia, polyclonal gammopathy, proteinuria, cylindruria
  • RBC์˜ organism ํ™•์ธ! (but ์—ผ์ƒ‰์ƒ ๊ด€์ฐฐ๋˜์ง€ ์•Š์„ ์ˆ˜ ์žˆ์Œ.)
    • ๋ชจ์„ธํ˜ˆ๊ด€์—์„œ ํ˜ˆ์•ก์ด ์กฐ๊ธˆ ๋” ์ •์ฒด๋ผ์„œ ์ž˜ ๋ณด์ผ ์ˆ˜ ์žˆ์Œ.
B. gibsoniB. canisB. coco
canis ๋ณด๋‹ค ๋” ์ž‘์Œ.
์ž‘์€ ์  ๋ชจ์–‘
์กฐ๋กฑ๋ฐ• ๋ชจ์–‘
๋ง์ดˆ์—์„œ๋Š” ring ๋ชจ์–‘
์ข€ ๋” ์ž์œ ๋ถ„๋ฐฉํ•œ ํ˜•ํƒœ
  • ์ž„์ƒ์ ์œผ๋กœ ์ •์ƒ์ด๋‚˜ ํ•ญ์ฒด ๋ฐ˜์‘ ์–‘์„ฑ์ธ ๊ฒฝ์šฐ๊ฐ€ ๋งŽ์Œ. > ํ˜„์žฌ ๊ฐ์—ผ์ด ์•„๋‹ ์ˆ˜๋„ ์žˆ์œผ๋‹ˆ,
    • ํ•ญ์ฒด ๊ฒ€์‚ฌ๋งŒ์œผ๋กœ ํ™•์ง„ํ•˜๊ธฐ๋Š” ์–ด๋ ค์›€.

PCR assays

  • ๋ฏธ๊ตญ์—์„œ ์ฃผ๋กœ ์ง„ํ–‰. B. vogeli ์™€ B. gibsoni ๋ฅผ ์ฐพ์•„์ฃผ์ง€๋งŒ, ์ข… ๊ตฌ๋ถ„์€ ๋ถˆ๊ฐ€.
  • ์œ„์Œ์„ฑ : peracute disease, concurrent immunosuppression, ์งˆ๋ณ‘ ์ดˆ๊ธฐ ํ•ญ์› ์–‘์ด ์ ๊ฑฐ๋‚˜, ๊ฒ€์‚ฌ ๊ธฐ์ค€์˜ ์ฐจ์ด๋กœ ์ธํ•ด
  • ์œ„์–‘์„ฑ(seropositive) : ์งˆ๋ณ‘์— ๊ฑธ๋ ธ๋‹ค๊ฐ€ ์น˜๋ฃŒ๋˜์–ด ๋ชธ์— ํ•ญ์›์ด ๋‚จ์•„์žˆ๋Š” ๊ฒฝ์šฐ โ‡’ ํ•ญ์› ์ž์ฒด๋กœ๋Š” ํ™•์ • ์ง„๋‹จ ๋ถˆ๊ฐ€.

[๊ตญ๋‚ด PCR assays ํ™˜๊ฒฝ]

  • Babesia ๋ฅผ ๊ฐ๋ณ„ํ•˜๋Š” ๋ฐ ๊ฐ€์žฅ ์ข‹์Œ - RBC์— ๊ธฐ์ƒ, ์ „ํ˜ˆ ์ƒ˜ํ”Œ ํ•„์š”.

    • ํ˜ˆ๊ฒ€ ์œ„ํ•ด ๋ฝ‘์„ ๋•Œ PCR์šฉ๋„ ๊ผญ ๋‚จ๊ฒจ๋†“์ž (์ „ํ˜ˆ 1ml)
  • ์žฅ์ ) ๊ฐ„๋‹จํ•˜๊ณ , ์‚ฌ๋žŒ ์†์„ ๋œ ํƒ€๋Š” ํŽธ.

  • ์ฃผ์˜์ ) ์Šคํ…Œ๋กœ์ด๋“œ ์น˜๋ฃŒ ์‹œ์ž‘ ์‹œ โ†’ ๊ฒ€์‚ฌ ๊ฒฐ๊ณผ๊ฐ€ ๊ฐ€๋ ค์งˆ ์ˆ˜ ์žˆ์Œ.

  • Subclinical carriers๊ฐ€ ์žˆ๋Š” ๊ฒฝ์šฐ, ์–‘์„ฑ ๊ฒฐ๊ณผ๊ฐ€ ๊ผญ ์ž„์ƒ ์ฆ์ƒ์„ ๋‚˜ํƒ€๋‚ด์ง€๋Š” ์•Š์Œ.

  • ํ•˜์ง€๋งŒ ์ฆ์ƒ์ด ์žˆ์„ ๋•Œ์˜ ๊ฒ€์‚ฌ๋Š” ์ž„์ƒ์  ์˜์˜๊ฐ€ ์žˆ์Œ.

[๊ณ ์–‘์ด]

  • Acute phase proteins : serum amyloid A (๊ณ ์–‘์ด โ†‘), haptoglobin, paraoxonase-1
    • ๊ต‰์žฅํžˆ ์†Œ์ˆ˜์˜ ๋™๋ฌผ์—์„œ, subclinical Babesia carrier์™€ ์ž„์ƒ ์ฆ์ƒ์ด ๋‚˜ํƒ€๋‚œ ๋™๋ฌผ์—์„œ ์œ ์˜๋ฏธํ•œ ์ฐจ์ด๊ฐ€ ์žˆ์Œ.
    • serum haptoglobin ์ฆ๊ฐ€ & paraoxonase-1 ๊ฐ์†Œ

4. Treatment

2๊ฐ€์ง€๋กœ ์ ‘๊ทผ.

  • Supportive care : ์ˆ˜ํ˜ˆ, ์ค‘ํƒ„์‚ฐ์—ผ ์น˜๋ฃŒ, ์ˆ˜์•ก ์น˜๋ฃŒ
  • Drugs : atovaquone (๋‹ค๋ฅธ ์•ฝ๋ฌผ์€ ์ค‘์š”x)

Drugs

In US
(1) B. vogeli ๊ฐ€ ์˜์‹ฌ๋  ๋•Œ : Imidocarb diproprionate
- 5-6.6mg/kg twice, 14days apart ๋˜๋Š” 7.5mg/kg once SC or IM
- gibsoni์— ๋Œ€ํ•ด์„œ๋Š” ๋‹จ๋… ์ œ์ œ๋กœ ํšจ๊ณผ์ ์ด์ง€ ์•Š์Œ.
(2) B. gibsoni ๊ฐ€ ์˜์‹ฌ๋  ๋•Œ : azithromycin + atovaquone
[ Azithromycin (10 mg/kg PO q24h) + atovaquone (13.3 mg/kg PO q8h)๏ผฝfor at least 10 days
- ๊ธฐ๋ฆ„์ง„ ์Œ์‹, ์•„์ด์Šคํฌ๋ฆผ๊ณผ ๊ฐ™์ด ๋จน๋Š”๋‹ค : ๊ตฌํ† ๋ฅผ ๋งŽ์ด ํ•˜๊ธฐ ๋•Œ๋ฌธ
  • ๊ตญ๋‚ด protocols : Azithromycin + atovaquone์ด first choice์ง€๋งŒ, ์•ˆ ๋˜๊ธฐ๋„ ํ•ด์„œ ๋‹ค์–‘ํ•œ ์•ฝ๋ฌผ ์กฐํ•ฉ์ด ์ œ์‹œ๋จ..
In Asia
(1) AA protocol : Azithromycin (10 mg/kg PO q24h) + atovaquone (13.3 mg/kg PO q8h) for 10 days
: ๊ตญ๋‚ด์—์„œ 1์ˆœ์œ„๋กœ ์„ ํƒ๋˜๋Š” ๋ฐฉ๋ฒ•
(2) Clindamycin (30 mg/kg PO q12h) + diminazene (3.5 mg/kg IM, a single dose on the day of presentation) + imidocarb (6 mg/kg SC, a single dose on the day after the diminazene was administered)
(3) Doxycycline (7-10 mg/kg q12h) + enrofloxacin (2-2.5 mg/kg q12h) + metronidazole (5-15 mg/kg q12h)
: 2๊ฐ€์ง€๊ฐ€ ๊ต์žฌ์—์„œ second, third choice๋กœ ์ œ์‹œ๋˜์—ˆ์ง€๋งŒ..
* MCD protocol : Metronidazole + Clindamycin + Doxycycline (for 30/60/90 days)
: ์‹ค์งˆ์ ์ธ 2์ˆœ์œ„๋Š” MCD protocole.
: AA์—์„œ failํ•œ ๋™๋ฌผ๋“ค์˜ 80%์—์„œ MCD protocol์ด ์น˜๋ฃŒ ํšจ๊ณผ๋ฅผ ๋ด„.

โ‡’ 100% ๋‚ซ๊ฒŒ ํ•˜๋Š” ์กฐํ•ฉ์€ ์•„์ง ์—†์Œ.

5. Zoonotic Aspects and Prevention

  • ๊ฐœ, ๊ณ ์–‘์ด โ†’ ์‚ฌ๋žŒ์œผ๋กœ ์ „ํŒŒ๋œ ์ผ€์ด์Šค๋Š” ์—†์ง€๋งŒ, ์ฃผ์˜๋Š” ํ•„์š”ํ•จ!
    • B. microti ๋Š” ์‚ฌ๋žŒ์—๊ฒŒ ๊ฐ์—ผ ๊ฐ€๋Šฅ
  • Minimal cross-protection : ํ•œ ๋ฒˆ ๊ฑธ๋ ธ์–ด๋„ ๋‹ค๋ฅธ species์— ๊ฑธ๋ฆด ๊ฐ€๋Šฅ์„ฑ ์žˆ์Œ
  • ๋ฉด์—ญ์–ต์ œ์ œ, ๋น„์žฅ์ ˆ์ œ์ˆ  : ๊ณผ๊ฑฐ ๊ฐ์—ผ๋˜์—ˆ๋˜ ๊ฐœ์—์„œ๋Š” ์œ„ํ—˜
  • ๊ฐœ๋ฌผ๋ฆผ์‚ฌ๊ณ  : ์กฐ์‹ฌํ•ด๋ผ
  • ๋ฐฑ์‹ ? : ์žˆ๋Š” ๋‚˜๋ผ๋„ ์žˆ์ง€๋งŒ, ๋ฏธ๊ตญ๊ณผ ์šฐ๋ฆฌ๋‚˜๋ผ์—๋Š” ์—†์Œ
  • Blood donor programs : ๊ผญ PCR screening์„ ๊ฑฐ์น˜๊ณ  ๋‚˜์„œ ๊ณตํ˜ˆ

[๊ตฌ์ถฉ์ œ]

  • Revolution + Advocate = Nexgard spectra